Group 1 - The recombinant protein concept sector rose by 2.85%, ranking fifth among concept sectors, with 46 stocks increasing in value [1] - Notable gainers included Shenzhou Cell and Weiming Pharmaceutical, both reaching the daily limit, while Saiseng Pharmaceutical, Hotgen Biotech, and Huiyu Pharmaceutical also saw significant increases of 10.45%, 10.38%, and 8.43% respectively [1] - The sector experienced a net inflow of 568 million yuan, with 30 stocks receiving net inflows, and five stocks attracting over 30 million yuan each [2] Group 2 - Leading the net inflow was Weiming Pharmaceutical, which saw a net inflow of 89.46 million yuan, followed by Kexing Pharmaceutical, Yipin Hong, and Huiyu Pharmaceutical with net inflows of 74.06 million yuan, 71.16 million yuan, and 60.03 million yuan respectively [2][3] - The net inflow ratios for Weiming Pharmaceutical, Kexing Pharmaceutical, and Huiyu Pharmaceutical were 24.18%, 13.33%, and 12.60% respectively [3] - The overall performance of the recombinant protein sector was supported by strong trading activity, with several stocks showing high turnover rates [3][4]

Investment Rating - The report maintains a "Recommended" investment rating for the healthcare sector [7]. Core Insights - The healthcare sector has shown a mixed performance, with the Shenyin Wanguo Pharmaceutical Bio Index rising by 1.60% from June 23 to June 27, 2025, underperforming the CSI 300 Index by 0.35 percentage points [2][12]. - Year-to-date, the pharmaceutical sector has increased by 6.24%, outperforming the CSI 300 Index by 6.57 percentage points, ranking 11th among 31 sectors [2][14]. - As of June 27, 2025, the valuation of the pharmaceutical sector stands at 27.54 times (TTM overall method, excluding negative values), with a premium of 140.94% compared to the CSI 300 [2][17]. Summary by Sections 1. Market Performance - The pharmaceutical sector's performance from June 23 to June 27, 2025, was a 1.60% increase, ranking 23rd among 31 sectors [12]. - The year-to-date performance shows a 6.24% increase, ranking 11th among 31 sectors [14]. 2. Important Events - The National Healthcare Security Administration released the "2025 Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory Adjustment Application Guidelines," marking a significant step for commercial health insurance in the multi-level medical security system [4][21]. 3. Industry Perspective - The inclusion of the commercial insurance innovative drug directory indicates an enhanced role for commercial insurance in the multi-level medical security system, providing greater opportunities for the industry [5][22]. - The report expresses optimism for innovative drugs, overseas expansion, and the clearing of procurement in specific segments, suggesting a focus on companies involved in these areas [22].

Group 1 - The innovative drug concept is experiencing a volatile rebound, with Sai Sheng Pharmaceutical (300485) hitting a 20% limit up, while companies like Anglikang (002940), Watson Bio (300142), Yuekang Pharmaceutical, Saint Nuo Bio, and Rongchang Bio also saw significant gains [1] - There is a disclosure of dark pool fund flows, indicating early signals of stock accumulation by major investors [1]

Group 1 - Shengnuo Bio expects a net profit attributable to shareholders of 77.03 million to 94.14 million yuan for the first half of 2025, representing a year-on-year increase of 253.54% to 332.10% [1] - The significant growth in Shengnuo Bio's performance is primarily attributed to the strong performance of its peptide raw material business, which is closely related to GLP-1 formulations [1] Group 2 - Shanghai Laishi has completed the acquisition of 100% equity in Nanyue Bio for 4.2 billion yuan, with an additional contingent payment of 50 million yuan if the company processes 305 tons of plasma by 2025 [2] - The completion of the acquisition and registration marks a significant step forward in Shanghai Laishi's "plasma expansion" strategy, although it is expected to add substantial goodwill, raising concerns about future impairment risks [2] Group 3 - Beijing Saisheng Pharmaceutical has signed a new drug technology transfer agreement with its affiliate, transferring technology related to the NeoAB33 new drug project for a total of 20 million yuan [3] - The transfer may optimize the asset structure of Huada Protein, which reported a loss of 8.3 million yuan in 2024, while Saisheng Pharmaceutical reported a net profit of 39.97 million yuan in the first quarter of 2025, indicating its financial capability to advance research and development [3] Group 4 - Eli Lilly's reversible BTK inhibitor, Pirtobrutinib, has had its new indication application accepted for review in China, targeting patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have previously received BTK inhibitor treatment [4] - If approved, Pirtobrutinib will provide a new treatment option for patients who have failed previous covalent BTK inhibitor therapies, further solidifying its market position in the treatment of B-cell malignancies [4] Group 5 - Innovent Biologics' CLDN-18.2 ADC product, IBI343, is proposed to be included as a breakthrough therapy for locally advanced or metastatic pancreatic cancer expressing CLDN 18.2, after at least two systemic treatments [5] - As the first CLDN18.2 ADC to achieve a breakthrough in pancreatic cancer, IBI343 is expected to fill a gap in second-line and later treatments, providing new options for patients [5]

Core Viewpoint - Multiple companies have announced significant developments, including investments, clarifications on business operations, and changes in control, which may present various investment opportunities and risks for stakeholders [2]. Company Announcements - **Hai Zheng Pharmaceutical** plans to establish a joint venture in synthetic biology with a registered capital of 350 million yuan, where Hai Zheng will contribute 260 million yuan, holding a 74.29% stake [3]. - **Jin Zhong Zi Jiu** clarified that its business scope remains unchanged despite media reports suggesting a shift away from liquor production, confirming that it will continue to focus on its core liquor business [4]. - **ST Gong Zhi** announced that its stock will resume trading on June 20, 2025, and enter a delisting period, with the last trading date expected to be July 10, 2025 [5]. - **Zhong Jing Electronics** confirmed that its production and operational conditions are normal, with no undisclosed significant matters [6]. - **Shan Jin International** is preparing for an overseas H-share issuance and listing on the Hong Kong Stock Exchange to enhance its global strategy [7]. - **Kang Da New Materials** intends to acquire at least 51% of Chengdu Zhongke Huamei Electronics to expand into the semiconductor integrated circuit sector [8]. - **Zhong Yan Chemical** agreed to a capital reduction for its subsidiary, which will result in it holding 100% of the subsidiary's equity, constituting a significant asset restructuring [9]. - **Tai Ji Co., Ltd.** announced a change in its actual controller to the Hubei Provincial State-owned Assets Supervision and Administration Commission, with stock resuming trading [10]. - **ST Yi Guo** plans to sell four Carrefour subsidiaries for 1 yuan, expecting to increase its net profit by approximately 572 million yuan, while focusing on its core home appliance business [11][12]. Performance Expectations - **Sheng Nuo Bio** anticipates a substantial increase in net profit for the first half of 2025, projecting a year-on-year growth of 253.54% to 332.10%, driven by strong performance in its peptide raw material business [13]. Share Buyback - **Nuo Wei Zan** intends to repurchase shares worth between 5 million and 10 million yuan to implement employee stock ownership plans, with a maximum repurchase price of 30 yuan per share [14]. Major Contracts - **Sai Sheng Pharmaceutical** signed a technology transfer contract for a new drug project with a total transaction amount of 20 million yuan, which will enhance its capabilities in the protein/antibody drug platform [15].

Meeting Details - The fifth meeting of the Supervisory Board of Beijing Saiseng Pharmaceutical Co., Ltd. was held on June 19, 2025, with all three attending supervisors present [1][2] - The meeting was legally convened in accordance with relevant laws and regulations [1] Resolutions Passed - The Supervisory Board approved the proposal regarding the signing of a "New Drug Technology Transfer Contract" and related transactions [1][2] - The board confirmed that the transaction is necessary for the company's normal operations and aligns with its development strategy [2] Compliance and Impact - The Supervisory Board concluded that the transaction complies with legal and regulatory requirements and does not affect the company's independence or harm the interests of shareholders, particularly minority shareholders [2]

Core Viewpoint - The company has signed a new drug technology transfer contract with its affiliate, with a total transaction amount of 20 million yuan [1] Group 1: Transaction Details - The company has entered into a technology transfer agreement for the NeoAB33 new drug project with its affiliate, Huada Protein, for a total of 20 million yuan [1] - The transaction is classified as a related party transaction due to the involvement of the company's chairman, general manager, and chief engineer in Huada Protein's management [1] Group 2: Strategic Implications - The acquisition of the relevant technology will accelerate the development of the company's protein/antibody drug platform, enhancing its capabilities from molecular design to cell line construction [1] - The company aims to expand its pipeline reserves in the cardiovascular field, promoting a differentiated competitive layout in this niche market and accelerating the transformation of research and development results [1]

证券代码：300485 证券简称：赛升药业 公告编码：2025-025 北京赛升药业股份有限公司 关于签订《新药技术转让合同》暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、关联交易概述 基于业务发展需要，北京赛升药业股份有限公司（以下简称"公司"或 "甲方"）与参股公司北京华大蛋白质研发中心有限公司（以下简称"华大蛋 白"或"乙方"）签署《新药技术转让合同》，华大蛋白将其拥有的NeoAB33新 药项目相关技术转让给公司，交易总额为2,000万元。 鉴于公司持有华大蛋白27.89%股权，公司董事长兼总经理马骉先生担任华 大蛋白的董事，公司总工程师孔双泉先生担任华大蛋白的董事，公司董事尹长 城先生担任华大蛋白董事兼总经理，根据《深圳证券交易所创业板股票上市规 则》，本次公司与华大蛋白签订《新药技术转让合同》构成关联交易。 公司于 2025 年 6 月 19 日召开了第五届董事会第八次会议及第五届监事会 第八次会议，审议通过了《关于签订<新药技术转让合同>暨关联交易的议案》。 董事会上，关联董事马骉、马丽、尹长城回避表决，全体独立董事表决同意 ...

证券代码：300485 证券简称：赛升药业 公告编号：2025-024 北京赛升药业股份有限公司 第五届监事会第八次会议决议公告 三、备查文件 第五届监事会第八次会议决议 北京赛升药业股份有限公司（以下简称"公司"）第五届监事会第八次会议 于 2025 年 6 月 19 日在公司会议室召开，本次会议于 2025 年 6 月 13 日以通讯的 方式向所有监事送达了会议通知。会议应参会监事 3 人，实际参会监事 3 人，公 司董事会秘书列席会议。会议由监事会主席赵丽娜女士主持。本次会议的召开符 合《中华人民共和国公司法》等有关法律、行政法规、部门规章、规范性文件和 公司章程的规定，会议决议合法、有效。 二、会议审议情况 经全体监事认真审议并表决，会议通过了以下议案： 审议通过《关于签订〈新药技术转让合同〉暨关联交易的议案》 本议案具体内容详见发布于中国证监会指定的创业板信息披露网站的《关于 签订<新药技术转让合同>暨关联交易的公告》。 经审核，监事会认为：本次关联交易系公司正常经营需要，符合公司发展战 略，决策程序符合相关法律、法规及公司章程的规定，不会对公司的独立性造成 影响，不存在损害公司及股东利益，特别是中 ...

证券代码：300485 证券简称：赛升药业 公告编号：2025-023 北京赛升药业股份有限公司 第五届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开情况 北京赛升药业股份有限公司（以下简称"公司"）第五届董事会第八次会议 于2025年6月19日在公司会议室召开，本次会议于2025年6月13日以通讯的方式向 所有董事送达了会议通知。会议应参会董事8人，实际参会董事8人，会议由董事 长马骉先生主持，公司监事、高级管理人员列席了本次会议。本次会议的召开符 合《中华人民共和国公司法》等有关法律、行政法规、部门规章、规范性文件和 公司章程的规定，会议决议合法、有效。 二、会议审议情况 经全体董事认真审议并表决，会议通过了以下议案： 审议通过《关于签订〈新药技术转让合同〉暨关联交易的议案》 本议案具体内容详见发布于中国证监会指定的创业板信息披露网站的《关于 签订<新药技术转让合同>暨关联交易的公告》。 特此公告。 北京赛升药业股份有限公司 董 事 会 2025 年 6 月 20 日 公司独立董事专门会议审议通过了本议案。 表决结果 ...